DOJ: By Its Own Admission, Yale Med School Illegally Discriminates Against White, Asian Applicants

The Department of Justice formally notified Yale School of Medicine on May 14, 2026, that the institution continues to engage in racially discriminatory admissions practices — a finding that drew renewed attention as the university marked its 325th commencement.

DOJ Letter Cites Dramatic Disparities in Admissions Odds

The DOJ letter concluded that Yale Medical School “continues to intentionally discriminate against applicants based on their race.” Federal investigators found that Black and Hispanic applicants were substantially more likely to receive interview offers than white and Asian candidates with identical MCAT scores and grade point averages — a disparity the department said “cannot be explained by coincidence.”

The figures are striking. According to the DOJ, a Black applicant held as much as a 29 times greater chance of receiving an admissions interview compared to an equally credentialed Asian applicant. The department determined this gap directly resulted from Yale’s use of race as a factor in its admissions process.

The Legal Standard Is Clear

The DOJ’s finding rests on a straightforward legal principle: under current law, race may not be used as an admissions criterion under any circumstances — regardless of how strong an applicant’s academic profile may be. Some critics of the DOJ’s position have argued that because admitted students across all racial groups held high scores, race was merely functioning as a tiebreaker among equally qualified candidates. That argument does not hold up legally.

Yale Medical School is not required to admit applicants purely on the basis of standardized test scores. The institution is free to weigh a broad range of factors in building its class. What it cannot do — under the Supreme Court’s 2023 ruling in Students for Fair Admissions v. Harvard and subsequent enforcement guidance — is treat an applicant’s racial or ethnic background as a factor in that evaluation.

Some defenders of the school’s practices also raised the argument that selecting students who achieved academic success despite socioeconomic hardship represents a legitimate and race-neutral measure of merit. The DOJ and the courts have not rejected that reasoning — in fact, considering an applicant’s ability to overcome poverty, underfunded schools, or family instability is legally permissible. The distinction that matters is whether the institution is evaluating those challenges on their own merits, or using them as proxies for race. Given the magnitude of the disparities uncovered — odds of admission differing by a factor of nearly 30 for similarly credentialed applicants — federal investigators concluded that Yale’s process crosses that line.

Context: Ongoing Federal Scrutiny of Elite Institutions

The Yale Medical School letter is part of a broader federal effort to enforce the Supreme Court’s prohibition on race-conscious admissions at universities receiving federal funding. Elite medical and professional schools have faced particular scrutiny, given the high stakes of admissions decisions and the well-documented score disparities across applicant pools.

The DOJ’s action signals that enforcement is not limited to undergraduate admissions offices. Graduate and professional programs that accepted the legal framework of pre-SFFA race-conscious admissions — and have been slow to restructure their processes — now face direct federal accountability.

What Comes Next

The May 14 letter represents a formal finding, not yet a lawsuit or consent decree. Yale has not publicly announced changes to its admissions process in response. The DOJ finding does, however, place the institution on notice that continued use of race-based criteria could expose it to litigation and the potential loss of federal funding.

The case underscores a tension that has emerged at medical schools across the country: how to build a diverse physician workforce through legally compliant means. Institutions that have invested heavily in outreach to underrepresented communities, pipeline programs, and holistic review processes argue those efforts are race-neutral. Federal investigators are evaluating whether the outcomes those processes produce are consistent with that claim — or whether, as the DOJ concluded at Yale, the numbers tell a different story.

For Yale Medical School, celebrating a milestone commencement while facing a federal discrimination finding presents a reputational and legal challenge that is unlikely to resolve quickly.